Digene Reaches Investors And Consumers With Ads; OTC Index Up 4.4%
This article was originally published in The Gray Sheet
Executive Summary
Digene's direct-to-consumer advertising campaign persuaded consumers and investors that its HPV Test is the standard of care for cervical cancer screening, driving the firm's stock up 34% to close the first quarter at $39.10
You may also be interested in...
Digene Fights Antitrust Charges As Part Of HPV Diagnostics Patent Case
Human papillomavirus test maker Digene, recently acquired by Qiagen, is defending itself against allegations of anti-competitive business practices from Third Wave Technologies as part of a larger patent battle between the firms
Digene Fights Antitrust Charges As Part Of HPV Diagnostics Patent Case
Human papillomavirus test maker Digene, recently acquired by Qiagen, is defending itself against allegations of anti-competitive business practices from Third Wave Technologies as part of a larger patent battle between the firms
Third Wave Technologies’ HPV tests
Firm commences clinical trials of two human papillomavirus (HPV) tests, for which it expects to apply to FDA for marketing go-ahead in 2007. The products include a screening test to detect the presence of 14 high-risk types of HPV and a genotyping test to detect HPV types 16 and 18. HPV types 16 and 18 are responsible for about 70% of cervical cancer cases, Third Wave says. The firm and competitor Digene recently agreed to forego patent litigation against each other for one year (1"The Gray Sheet" April 17, 2006, p. 18)...